Share Twitter LinkedIn Facebook Email Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Safety Profile of Once-Weekly Regimen Was comparable opposed to the twice-weekly regimen at Annual Meeting 2018 Advertisement
TIL Therapy Breakthroughs for Oncologists and Oncology Professionals Melanoma Skin Cancer Treatment 1 Min Read
63% pCR Rate with Neoadjuvant Nivolumab + Relatlimab in Resectable Melanoma Melanoma Skin Cancer Treatment 4 Mins Read